Oral Direct Renin Inhibition: Premise, Promise, and Potential Limitations of a New Antihypertensive Drug

American Journal of Medicine

Volumn 121, Issue 4, 2008, Pages 265-271

  Shafiq, Moiz M ^a   Menon, Dileep V ^a   Victor, Ronald G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aliskiren; Angiotensin; Hypertension; Renin

Indexed keywords

ADRENALIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; PLACEBO; RENIN; RENIN INHIBITOR; VALSARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL ABSORPTION; HUMAN; HYPERTENSION; KIDNEY CONCENTRATING CAPACITY; LIPID DIET; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW;

ADMINISTRATION, ORAL; AMIDES; BLOOD PRESSURE DETERMINATION; DRUG APPROVAL; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41149143631     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.11.016     Document Type: Review

References (59)

1. Azizi M., Webb R., Nussberger J., and Hollenberg N.K. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 24 (2006) 243-256
2. Staessen J.A., Li Y., and Richart T. Oral renin inhibitors. Lancet 368 (2006) 1449-1456
3. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 3 (2003) 389-394
4. Sealey J.E., and Laragh J.H. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 20 (2007) 587-597
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
6. Calhoun D.A. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 48 (2006) 387-396
7. O'Brien E., Barton J., Nussberger J., et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49 (2007) 276-284 Epub 2006 Dec 11
8. Siragy H.M., Xue C., Abadir P., and Carey R.M. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 45 (2005) 133-137
9. Paravicini T.M., and Touyz R.M. Redox signaling in hypertension. Cardiovasc Res 71 (2006) 247-258
10. Abuissa H., Jones P.G., Marso S.P., and O'Keefe Jr. J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
11. Candido R., Allen T.J., Lassila M., et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109 (2004) 1536-1542
12. Harrison D.G., Widder J., Grumbach I., et al. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 259 (2006) 351-363
13. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
14. Lau T., Carlsson P.O., and Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47 (2004) 240-248
15. McGavock J.M., Victor R.G., Unger R.H., and Szczepaniak L.S. Adiposity of the heart, revisited. Ann Intern Med 144 (2006) 517-524
16. Weiss D., Kools J.J., and Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103 (2001) 448-454
17. Zhou M.S., Jaimes E.A., and Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens 17 (2004) 167-171
18. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
19. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
20. Investigators T.S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
21. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
22. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752
23. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
24. Sever P.S., Poulter N.R., Elliott W.J., et al. Blood pressure reduction is not the only determinant of outcome. Circulation 113 (2006) 2754-2772
25. Strauss M.H., and Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114 (2006) 838-854
26. Verdecchia P., Reboldi G., Angeli F., et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46 (2005) 386-392
27. Staessen J.A., Li Y., Thijs L., and Wang J.G. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 28 (2005) 385-407
28. Wang J.G., Li Y., Franklin S.S., and Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 50 (2007) 181-188
29. Tsuyuki R.T., and McDonald M.A. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 114 (2006) 855-860
30. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
31. Julius S., Weber M.A., Kjeldsen S.E., et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 48 (2006) 385-391
32. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 (2004) 2049-2051
33. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
34. Chiurchiu C., Remuzzi G., and Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 16 Suppl 1 (2005) S58-S63
35. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
36. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
37. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
38. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
39. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124
40. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
41. Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
42. Nussberger J., Wuerzner G., Jensen C., and Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39 (2002) E1-E8
43. Stanton A., Jensen C., Nussberger J., and O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42 (2003) 1137-1143
44. Danser A.H., and Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 46 (2005) 1069-1076
45. Wood J.M., Maibaum J., Rahuel J., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308 (2003) 698-705
46. Villamil A., Chrysant S.G., Calhoun D., et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25 (2007) 217-226
47. Oparil S., Yarows S.A., Patel S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370 (2007) 221-229
48. Zhao C., Vaidyanathan S., Yeh C.M., et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 45 (2006) 1125-1134
49. Azizi M., Menard J., Bissery A., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
50. Gradman A.H., Schmieder R.E., Lins R.L., et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
51. Oh B.H., Mitchell J., Herron J.R., et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49 (2007) 1157-1163
52. Novartis Pharmaceuticals Corporation. Tekturna (aliskiren) Prescribing Information. 2007.
53. Carey R.M. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45 (2005) 840-844
54. Ferrario C.M., Jessup J., Gallagher P.E., et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68 (2005) 2189-2196
55. Ichihara A., Kaneshiro Y., Takemitsu T., et al. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 17 (2006) 2495-2503
56. Ichihara A., Suzuki F., Nakagawa T., et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 17 (2006) 1950-1961
57. Ichihara A., Kaneshiro Y., Takemitsu T., et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47 (2006) 894-900
58. Nguyen G. Renin/prorenin receptors. Kidney Int 69 (2006) 1503-1506
59. Schefe J.H., Menk M., Reinemund J., et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 99 (2006) 1355-1366